Jurjen Versluis MD, PhD

Dr. Jurjen Versluis, MD, PhD, is a hematologist in the Department of Hematology at the Erasmus MC Cancer Institute, Rotterdam. He received his MD from the VU University, Amsterdam, and completed training in Internal Medicine and Hematology at the Erasmus MC University in Rotterdam. His clinical focus in Hematology are acute lymphoblastic and myeloid leukemia (ALL/AML), myelodysplastic syndromes (MDS), and allogeneic hematopoietic cell transplantation. He is the deputy director of the hematopoietic cell transplantation program at the Erasmus MC Cancer Institute.

Versluis Clinical Research is focused on improving outcomes for patients with myeloid malignancies by applying personalized treatment approaches using advanced statistical methodologies. Both his PhD (obtained in 2017, cum laude) and postdoctoral research (2020/2021) at Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, focused on (1) identifying subgroups of patients who particularly benefit from allogeneic transplantation as a treatment strategy and (2) developing risk models specific to toxicity of acute myeloid leukemia treatment and allogeneic transplantation.